Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Italy / NCT06783803
Active, not recruiting Observational

Application of Linkage Analysis in the Identification of Novel Hereditary Factors in Familial Aneurysms

NCT06783803 · tracked via the Priya Life Science Italy tracker
Sponsor
IRCCS Policlinico S. Donato
Phase
Observational
Started
2024-06-15
Last updated
2025-01-20

Condition(s) studied

Familial Thoracic Aortic Aneurysm and Aortic Dissection

Investigational drug(s) / intervention(s)

Linkage Analysis

Linkage Analysis: WES-Linkage analysis in families with FTAAD in follow-up in an Italian reference centre for genetic aorthopathies

Study summary

The aim of this study is to describe the effectiveness of the application of Linkage Analysis, compared to the standard procedures currently provided by the italian NHS, in the identification of thoracic aortic aneurysms and dissection (TAAD) transmission markers in individuals with familial TAAD.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with ascending thoracic aortic aneurysms in the absence of a mutation identified by WES * Subjects with small and medium artery aneurysms in the absence of a mutation identified by WES * Relatives of individuals with ascending thoracic aortic aneurysms in the absence of a mutation identified by WES * Relatives of individuals with ascending thoracic aortic aneurysms in the absence of a mutation identified by WES * Signed informed consent Exclusion Criteria: * Subjects wit syndromic FTAAD with WES identified gene mutation * Subjects wit non-syndromic FTAAD with WES identified gene mutation

Primary outcome measure(s)

  • DNA sequences in FTAAD — 16 months
    Identify those chromosome regions containing the DNA sequences responsible for each enrolled member of FTAAD families

Trial sites (1)

FacilityCityRegionStatus
Cardiovascular Genetic Centre San Donato Milanese Milan

More IRCCS Policlinico S. Donato trials in Italy

Novel Risk Prediction Approaches for the Primary Prevention of Cardiovascular Diseases in Italy: the CVRISK-IT Trial (CVRISK-IT) Recruiting
Multivariate Approach to the Numerical Assessment of Cortical - Autonomic - VAscular Dynamic Interplay Recruiting
Heart Failure and Aortic Stenosis Transcriptome Recruiting
RNA as Prognostic Biomarkers in Patients With Acute Coronary Syndrome Recruiting
OUTcomes Evaluation of Current Therapeutic STrategies for Severe Aortic Valve steNosis anD the agING Population in ITALY Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06783803 on ClinicalTrials.gov ↗ ← All trials in Italy